Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Accounts Payables: 2019-2025

Historic Accounts Payables for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $18.4 million.

  • IDEAYA Biosciences' Accounts Payables rose 46.68% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 46.68%. This contributed to the annual value of $15.4 million for FY2024, which is 133.72% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported Accounts Payables of $18.4 million as of Q3 2025, which was up 6.73% from $17.3 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Accounts Payables registered a high of $18.4 million during Q3 2025, and its lowest value of $1.3 million during Q1 2021.
  • Its 3-year average for Accounts Payables is $11.4 million, with a median of $12.6 million in 2024.
  • Data for IDEAYA Biosciences' Accounts Payables shows a peak YoY surged of 180.30% (in 2025) over the last 5 years.
  • IDEAYA Biosciences' Accounts Payables (Quarterly) stood at $2.1 million in 2021, then soared by 103.81% to $4.3 million in 2022, then soared by 54.16% to $6.6 million in 2023, then soared by 133.72% to $15.4 million in 2024, then skyrocketed by 46.68% to $18.4 million in 2025.
  • Its Accounts Payables was $18.4 million in Q3 2025, compared to $17.3 million in Q2 2025 and $17.6 million in Q1 2025.